Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

27 January 2020

En Inde, la résistance aux antibiotiques devient un problème sanitaire très sérieux

This report from Lise Barnéoud of Le Monde looks at how antimicrobial resistance is threatening India's health care systems. It draws on the findings of the 2020 Antimicrobial Resistance Benchmark to outline pharmaceutical companies' actions in response to the situation.

Direct links

Read the full article

As India has one of the highest rates of antibacterial consumption and one of the highest resistance rates in the world, Le Monde looks at some of the reasons behind these numbers and workable ways to move forward. 

It looks at how pharmaceutical companies are addressing the urgent need for new antibiotics, drawing on two reports made public by the WHO and the results of the latest AMR Benchmark:

The Benchmark reports "progress in the fight against superbugs, but not yet on the scale necessary. Only 51 product candidates are currently in the final stages of clinical development, which remains weak. Given the unavailability of older antibiotics in low and middle income countries, the new ones are unlikely to reach the people who need them."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved